No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 29.340
- +0.940+3.31%
Close Dec 20 16:00 ET
- 29.340
- 0.0000.00%
Post 16:11 ET
2.05BMarket Cap-7.76P/E (TTM)
29.770High28.090Low1.56MVolume28.090Open28.400Pre Close45.63MTurnover2.84%Turnover RatioLossP/E (Static)69.80MShares37.00052wk High2.77P/B1.61BFloat Cap15.32052wk Low--Dividend TTM54.91MShs Float58.380Historical High--Div YieldTTM5.92%Amplitude7.520Historical Low29.249Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $38
Possible Bearish Signals With Akero Therapeutics Insiders Disposing Stock
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
Akero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH Treatment
Akero a New Buy at Citi on Liver Disease Asset
Akero Therapeutics Price Target Announced at $65.00/Share by Citigroup
Heat List
US
Overall
Symbol
Price
% Chg
No Data